Incyte Corporation (INCY) Stock: Falling Apart On Failed Clinical Trial
Incyte Corporation (NASDAQ: INCY) is falling apart in the market today after announcing that a Phase 3 clinical trial, in collaboration with Merck & Co., Inc. (NYSE: MRK) has ended with less-than-positive data. Of course, this struck fear in the minds of investors, sending the stock tumbling down. Today, we’ll talk about: The clinical results; what we’re … Read more